SCHEMBL4529566

SCHEMBL4529566

NC(=O)c1ccccc1[CH]c1ncc[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1A1 P48729 1/20 0.54
TYRO3 Q06418 1/20 0.54
DYRK1B Q9Y463 1/20 0.54
NUDT1 P36639 1/20 0.42
ALDH1A1 P00352 5/20 0.40
HPGD P15428 4/20 0.40
PARP1 P09874 4/20 0.40
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 2/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 2/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
BCAT2 O15382 1/20 0.38
PDPK1 O15530 1/20 0.37
MAPT P10636 2/20 0.37
TSHR P16473 1/20 0.37
TLK2 Q86UE8 2/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8579469 0.76 ALDH1A1 (0.54) ALDH1A1HPGDPARP1KDM4EHSD17B10
SCHEMBL29212534 0.71 CSNK1A1 (0.59) CSNK1A1TYRO3DYRK1BNUDT1ALDH1A1
SCHEMBL4144289 0.71 SMN1; SMN2 (0.41) CSNK1A1TYRO3DYRK1BNUDT1ALDH1A1
SCHEMBL4235623 0.71 CSNK1A1 (0.45) CSNK1A1TYRO3DYRK1BNUDT1PARP1
SCHEMBL6825869 0.70 CSNK1A1 (1.00) CSNK1A1TYRO3DYRK1BNUDT1ALDH1A1
SCHEMBL3462830 0.70 KMT2A (0.67) CSNK1A1TYRO3DYRK1BNUDT1ALDH1A1
SCHEMBL4535031 0.70 PARP1 (0.39) CSNK1A1TYRO3DYRK1BNUDT1ALDH1A1
SCHEMBL4510333 0.70 BCAT2 (0.41) CSNK1A1TYRO3DYRK1BNUDT1ALDH1A1
SCHEMBL770829 0.70 BCAT2 (0.52) ALDH1A1HPGDPARP1KDM4EHSD17B10
SCHEMBL4057360 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054445-A1 Amide Substituted Quinolines ASTRAZENECA AB (SE) 2009-02-26 US claimed
EP-1981882-A1 AMIDE SUBSTITUTED QUINOLINES AstraZeneca AB (SE) 2008-10-22 EP claimed
WO-2007086799-A1 AMIDE SUBSTITUTED QUINOLINES ASTRAZENECA AB (SE) 2007-08-02 WO claimed
US-20090054445-A1 Amide Substituted Quinolines ASTRAZENECA AB (SE) 2009-02-26 US disclosed
EP-1981882-A1 AMIDE SUBSTITUTED QUINOLINES AstraZeneca AB (SE) 2008-10-22 EP disclosed
WO-2007086799-A1 AMIDE SUBSTITUTED QUINOLINES ASTRAZENECA AB (SE) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054445-A1 Amide Substituted Quinolines RECQL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0 CSNK1A1 849/4885TYRO3 4100/4885DYRK1B 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.